Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Terminated 1Completed 1

Sponsor Class

NIH 2

Study Type

Interventional 2

Sponsor

Cancer Type

Head & Neck 2

Conditions

Polycystic Ovary Syndrome 3Leukoplakia, Oral 2Insulin Resistance 2Diabetes Mellitus 2Carcinoma, Non-Small-Cell Lung 2Urinary Bladder Neoplasms 1Thyroid Cancers That Contain the PAX8-PPARgamma Fusion Gene 1Sleep Apnea, Obstructive 1Skin Neoplasms 1Prostatic Neoplasms 1Pancreatic Neoplasms 1Neoplasms 1Metabolic Syndrome 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1Head and Neck Neoplasms 1Glucose Intolerance 1Diabetes Mellitus, Type 2 1Carotid Intimal Medial Thickness 1 1Carcinoma, Squamous Cell 1

Interventions

Pioglitazone 2Sulindac 1Photochemotherapy 1Nivolumab 1Metformin 1Dihematoporphyrin Ether 1Biopsy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Has results × Leukoplakia, Oral × Pioglitazone × Clear all
NCT00099021 2022-02-11

Pioglitazone Hydrochloride in Preventing Head and Neck Cancer in Patients With Oral Leukoplakia

National Cancer Institute (NCI)

Phase 2 Completed
21 enrolled 6 charts
Head & Neck

Head and Neck Neoplasms, Leukoplakia, Oral

NCT00951379 2016-04-06

Pioglitazone for Oral Premalignant Lesions

National Cancer Institute (NCI)

Phase 2 Terminated
52 enrolled 23 charts
Head & Neck

Leukoplakia, Oral

Data powered by HemOnc (CC BY 4.0) Colophon âš¡